Cargando…

EAT Thickness as a Predominant Feature for Evaluating Arterial Stiffness in Patients with Heart Failure with Preserved Ejection Fraction

OBJECTIVE: Heart failure with preserved ejection fraction (HFpEF) is an intricacy heterogeneous syndrome. However, the association between EAT and arterial stiffness in HFpEF patients remains unknown. METHODS: A total of 102 patients were enrolled into the study, and brachial-ankle pulse-wave veloci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Zhiqiang, Hu, Weiwei, Zhang, Hanwen, Tao, Hongmei, Lei, Peng, Liu, Jie, Yu, Yali, Dong, Qian, Gao, Lei, Zhang, Dongying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039733/ https://www.ncbi.nlm.nih.gov/pubmed/35494532 http://dx.doi.org/10.2147/DMSO.S356001

Ejemplares similares

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
por: Solomon, Scott D., et al.
Publicado: (2021)

Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER‐like endpoint definitions
por: Anker, Stefan D., et al.
Publicado: (2022)

EMPEROR-Preserved: SGLT2 inhibitors breakthrough in the management of heart failure with preserved ejection fraction
por: Wagdy, Kerolos, et al.
Publicado: (2021)

Association Between Arterial Stiffness and Heart Failure With Preserved Ejection Fraction
por: Chi, Chen, et al.
Publicado: (2021)

Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial
por: Pocock, Stuart J., et al.
Publicado: (2022)

MicroRNA-126 Level Increases During Exercise Rehabilitation of Heart Failure with a Preserved Ejection Fraction
por: Jin, Dong, et al.
Publicado: (2021)

Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the REBALANCE‐HF trial roll‐in cohort
por: Fudim, Marat, et al.
Publicado: (2022)

Beta‐blockers withdrawal in patients with heart failure with preserved ejection fraction and chronotropic incompetence: Effect on functional capacity rationale and study design of a prospective, randomized, controlled trial (The Preserve‐HR trial)
por: Palau, Patricia, et al.
Publicado: (2020)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Rationale and Study Design of Differences in Cardiopulmonary Exercise Capacity According to Coronary Microvascular Dysfunction and Body Composition in Patients with Suspected Heart Failure with Preserved Ejection Fraction
por: Kim, So Ree, et al.
Publicado: (2021)

Rising arterial stiffness with accumulating comorbidities associates with heart failure with preserved ejection fraction
por: Ali, Danish, et al.
Publicado: (2023)

Rationale and Study Design of the Withdrawal of Spironolactone for Heart Failure with Improved Left Ventricular Ejection Fraction
por: Hyun, Junho, et al.
Publicado: (2021)

Heart failure with preserved ejection fraction based on aging and comorbidities
por: Lin, Ying, et al.
Publicado: (2021)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

3426 Increased Monounsaturated Fat Consumption is Associated with Improved Body Composition in Subjects with Obesity and Heart Failure with Preserved Ejection Fraction
por: Billingsley, Hayley, et al.
Publicado: (2019)

Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
por: Ostrominski, John W., et al.
Publicado: (2022)

Ferroptosis: The Potential Target in Heart Failure with Preserved Ejection Fraction
por: Li, Qing, et al.
Publicado: (2022)

Extracellular volume fraction correlates with myocardial stiffness and allows for differentiation between impaired active relaxation and passive stiffness in heart failure with preserved ejection fraction
por: Rommel, Karl-Philipp, et al.
Publicado: (2016)

Heart failure with preserved ejection fraction: an update on pathophysiology, diagnosis, treatment, and prognosis
por: Ma, Chao, et al.
Publicado: (2020)

Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON‐HF trial
por: Chatur, Safia, et al.
Publicado: (2022)

Prognostic relevance of left atrial function and stiffness in heart failure with preserved ejection fraction patients with and without diabetes mellitus
por: Zhu, Shuangshuang, et al.
Publicado: (2022)

Biomarkers in heart failure with preserved ejection fraction
por: Meijers, W. C., et al.
Publicado: (2016)

Management of heart failure with preserved ejection fraction
por: Gard, Emma, et al.
Publicado: (2020)

Managing heart failure with preserved ejection fraction
por: Davidson, Alexander, et al.
Publicado: (2020)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Comorbidities in heart failure with preserved ejection fraction
por: Deichl, Andrea, et al.
Publicado: (2022)

Quantification of myocardial stiffness in heart failure with preserved ejection fraction porcine model using magnetic resonance elastography
por: Mazumder, Ria, et al.
Publicado: (2016)

Association between sleep‐disordered breathing and arterial stiffness in heart failure patients with reduced or preserved ejection fraction
por: Suzuki, Satoshi, et al.
Publicado: (2018)

Impact of Diabetes Mellitus on Ventricular Structure, Arterial Stiffness, and Pulsatile Hemodynamics in Heart Failure With Preserved Ejection Fraction
por: Chirinos, Julio A., et al.
Publicado: (2019)

Stiff left atrial syndrome as another cause for heart failure with preserved ejection fraction and normal BNP levels
por: Lucas, C. M. H. B.
Publicado: (2016)

Association of arterial stiffness and heart failure with preserved ejection fraction in the elderly population – results from the CARLA study
por: Schott, Artjom, et al.
Publicado: (2022)

Rationale and design of a navigator‐driven remote optimization of guideline‐directed medical therapy in patients with heart failure with reduced ejection fraction
por: Blood, Alexander J., et al.
Publicado: (2019)

The Value of Neutrophil-to-Lymphocyte Ratio and Epicardial Adipose Tissue Thickness in Heart Failure With Preserved Ejection Fraction
por: Colluoglu, Tugce, et al.
Publicado: (2023)

The Potential Therapeutic Role of Celastrol in Patients With Heart Failure With Preserved Ejection Fraction
por: Ajmal, Maryam, et al.
Publicado: (2021)

p53‐Dependent Mitochondrial Compensation in Heart Failure With Preserved Ejection Fraction
por: Chen, Xiaonan, et al.
Publicado: (2022)

Serum Osteoprotegerin and Carotid Intima-Media Thickness Are Related to High Arterial Stiffness in Heart Failure with Reduced Ejection Fraction
por: Fehérvári, Lajos, et al.
Publicado: (2021)

Risks of incident heart failure with preserved ejection fraction in Chinese patients hospitalized for cardiovascular diseases
por: Zhang, Jun-Xia, et al.
Publicado: (2019)

Predominance of Heart Failure With Preserved Ejection Fraction in Postmenopausal Women: Intra- and Extra-Cardiomyocyte Maladaptive Alterations Scaffolded by Estrogen Deficiency
por: Adekunle, Adebayo Oluwafemi, et al.
Publicado: (2021)

Traditional Chinese medicine for heart failure with preserved ejection fraction: clinical evidence and potential mechanisms
por: Fan, Yujian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_r23jsk62t27hec07uk40vr19bm